Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.51 Analyst target: $30.00 Upside: 1886.75%
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of several candidate products. The company is headquartered in Bedminster, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.